Bayer AG
Operates as a life sciences company across pharmaceuticals, consumer health, and crop science, with prescription drugs for cardiology and women's health, specialty oncology and ophthalmology treatments, over-the-counter medicines, nutritional supplements, and agricultural crop protection products.
As of Jul 17, 2026
Executive summary
Bayer AG is a diversified healthcare and life sciences company trading at €48.46 on XETRA. The stock shows a neutral technical bias despite strong momentum, having gained 30.4% over one month and 75.6% over the past year. With a market capitalisation of €47.6 billion, the company reflects broad recovery in its sector valuations.
Price history
As of Jul 17, 2026
Performance
+1.55%
-3.31%
+30.44%
+17.50%
+31.31%
+75.64%
As of Jul 17, 2026
Technical indicators
- 59.7
- -0.53Bearish
- 50: 41.32 · 200: 37.67Bullish
- €32.96 / €52.08
Technical Bias
Bayer AG's technical picture is mixed. The moving averages suggest an upward lean with the 50-day above the 200-day, but MACD's negative value of minus 0.53 signals downward momentum, whilst RSI sits at a neutral 59.7. This is a derived technical read, not a recommendation.
A transparent read of the indicators below — not a prediction or recommendation.
As of Jul 17, 2026
Fundamentals
- €47.6B
- —
- €-2.19
- -4.77%
- -2.4%
- €2.08B
- 0.83
- €24.73 – €53.92
- 0.23%
- Apr 27, 2026
- Aug 4, 2026 (16 days)
As of Jul 18, 2026
Upcoming catalysts
- Earnings report
As of Jul 18, 2026
Latest news
As of Jul 18, 2026
Short-term outlook
Bayer shares have surged 30.4% over the past month, and the picture is mixed up close: the 50-day average sitting well above the 200-day still points to a bullish longer-term trend, RSI at 59.7 is neutral, but MACD is flagging bearish momentum. With resistance at €52.08 overhead and support at €32.96 well below, the next few weeks may hinge on whether that momentum stalls near current levels, with no earnings catalyst due until August 2026.
Medium-term outlook
Bayer's top line is still shrinking, down 2.4% year-on-year, and the company is currently operating at a loss with a profit margin of -4.8%, which limits room for optimism over the coming quarters. The dividend yield sits at a modest 0.2%, and with no P/E to lean on given the negative earnings, the technical picture is reading neutral, suggesting the market is waiting for clearer signs of a turnaround before picking a direction.
Key risks
- Bayer's profit margin sits at -4.8% alongside a 2.4% year-on-year revenue decline, pointing to ongoing fundamental strain.
- The stock trades at €48.46, well above its 52-week low of €24.73 but still meaningfully below its €53.92 high, reflecting continued volatility in the shares.
- Growth initiatives such as the Himalayas-1 trial with ORIC Pharmaceuticals and the Series B financing for Sabanto depend on early-stage or newly scaled ventures, which carry execution risk before they can offset broader weakness.
- The absence of a reported P/E ratio makes it harder to benchmark Bayer's valuation against peers, adding a layer of uncertainty for anyone assessing the shares.
About Bayer AG
Bayer AG is a German pharmaceutical and life sciences group listed on XETRA under the ticker BAYN. Operating in the Healthcare sector within the Drug Manufacturers - General industry, the company ranks among Germany's larger listed drugmakers, with a market capitalisation of €47.6B reflecting its scale in a competitive global sector shaped by drug development, regulatory approvals, and shifting healthcare demand.
Bayer's key figures give a mixed read on its current position. There's no price-to-earnings ratio available, which limits how easily the stock can be benchmarked against typical profitability measures right now. The dividend yield stands at a modest +0.2%, a relatively small direct income return for shareholders. Together, these figures point to a company whose valuation picture is currently harder to gauge through standard earnings-based metrics, something worth keeping in mind when researching the stock further.
AI-assisted research for informational purposes only — not investment advice. Figures are sourced from third-party market data and may be delayed. Do your own research before trading. Your capital is at risk.